Clinical Development Director, Global Medical Communications Boston, Massachusetts

Position Overview

Bicara Therapeutics is seeking a highly motivated and detail-oriented Director of Global Medical Communications to lead publication strategies and execution for assigned oncology assets. This role will report to the Senior Vice President, Clinical & Medical Affairs.

This is a high-impact, fast-paced role ideal for a strong scientific communicator who thrives under tight timelines, is comfortable driving complex cross-functional projects forward, and can translate clinical data into compelling scientific narratives. This individual will be instrumental in defining and communicating the value of Bicara’s pipeline to the medical community, developing relationships with KOLs, and shaping how our science is communicated externally.

The Director of Global Medical Communications will lead the creation and execution of comprehensive global publication strategies, including pre-launch planning, congress deliverables, medical education activities (e.g., CME), peer-reviewed publications, MSL materials, and scientific platforms, while establishing scalable processes, managing vendors and internal resources, aligning with MLR review workflows, and ensuring internal stakeholders are engaged and coordinated.

This role is based in our Boston office and follows a hybrid schedule, with three in-office days each week.

Responsibilities

• Lead global publication strategy and tactical execution for assigned oncology assets, including manuscripts, abstracts, posters, oral presentations, CME initiatives, and other external scientific communications.
• Define and evolve the scientific narrative and key messaging in collaboration with Clinical Development, Medical Affairs, and senior leadership, ensuring consistency across all communications.
• Serve as the publications lead on cross-functional teams, including regular meetings with Clinical, Regulatory, Commercial, and medical colleagues; ensure alignment with scientific platforms, lexicons, gap assessments, and Medical Affairs plans.
• Establish and operationalize scalable publication processes, including authorship alignment, internal review workflows (e.g., MLR), and submission protocols, in compliance with ICMJE, GPP, and internal publication policies.
• Create and maintain a detailed publication plan and timeline, tracking status, prioritizing high-impact deliverables, and managing version control and publication records using internal tools.
• Drive scientific content with strategic direction and provide initial input, partnering cross-functionally to ensure clarity, accuracy, and compliance.
• Provide direction and oversight to external vendors and internal medical writers, ensuring deliverables are scientifically rigorous, timely, and on-budget.
• Partner with the Clinical Development and Finance teams to forecast outsourcing needs, mage publication budgets, and optimize internal resource allocation for assigned assets.
• Identify and address publication-related issues, providing timely solutions or mediation where needed, and ensuring alignment with cross-functional strategies.
• Collaborate with Medical Affairs leadership to develop MSL materials, scientific slide decks, congress compendia, FAQs, and other medical communication tools.
• Engage directly with KOLs and investigators to align on content development, data interpretation, authorship expectations, and congress strategy.
• Ensure accurate documentation of publication activities, in compliance with company policy and global best practices (ICMJE, GPP, etc.).

Qualifications

Company Overview

Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β).

Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.

Here at Bicara, we believe in building diverse teams and cultivating a culture where all voices are included. We encourage people from all backgrounds to apply.

Bicara Therapeutics is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.

#J-18808-Ljbffr